Company / Gross Profit
Myriad Genetics, Inc. Gross Profit History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$576.6M
FY2025
5-year range
$476.4M / $585.4M
FY2022-FY2025
Trend
-1.5%
vs FY2024
Sector context
#13 of 29
Health Care
What the data says
At $577M, Myriad Genetics, Inc.'s gross profit ranks #13 of 29 in the Health Care sector. Improved from $517M to $577M over the past 2 years.
Based on SEC 10-K filings.
$577M in FY2025 with a 3-year CAGR of +6.6%.
Improved from $517M to $577M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +6.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#13 of 29 in Health CareTop 45% of 29This company $576.6M Sector average $3.5B
▼
-83.3% below sector average
Key checks
Key Insights
- 3-year CAGR of +6.6%, indicating consistent growth.
- In FY2025, gross profit decreased 1.5% year-over-year.
- Ranks #13 out of 29 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $576.6M | -1.5% |
| FY2024 | $585.4M | +13.2% |
| FY2023 | $517.0M | +8.5% |
| FY2022 | $476.4M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026